ARCHIVES

ODAC Reviews Post-Marketing Studies for Eight Indications

This article is from The Cancer Letter archive.

Vol. 29 No. 12 | March 21, 2003

Download PDF Visit The Full Archive

Related Articles

Clinical Trials Approved By NCI Last Month

March 29, 2002

NCI Study Find Farmers Using Herbicides At High Risk for Some Lymphomas

September 12, 1986

ODAC Rejects Amsacrine NDA, Renews Idarubicin

September 14, 1990

Also in this 8-page issue: Use cancer mortality, not 5-year survival, to track progress against cancer, researchers say.

July 29, 2005

Clearinghouse Agrees On Three Big New Carcinogens

May 4, 1979

Blood Cancers Advocacy Groups Seek DOD And NCI Funds, Medicare Coverage.

July 6, 2001